End-of-day quote
Dhaka S.E.
06:00:00 2024-07-15 pm EDT
|
5-day change
|
1st Jan Change
|
27.8
BDT
|
-2.46%
|
|
-3.14%
|
+11.65%
|
Fiscal Period: June |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Capitalization
1 |
2,346
|
2,543
|
1,893
|
2,274
|
2,338
|
2,459
|
Enterprise Value (EV)
1 |
2,211
|
2,489
|
1,895
|
2,291
|
2,397
|
2,529
|
P/E ratio
|
21.5
x
|
16.1
x
|
16.2
x
|
20
x
|
24
x
|
24.9
x
|
Yield
|
0.58%
|
0.59%
|
-
|
0.8%
|
0.8%
|
0.76%
|
Capitalization / Revenue
|
5.92
x
|
4.22
x
|
3.54
x
|
4.59
x
|
4.41
x
|
4.41
x
|
EV / Revenue
|
5.58
x
|
4.13
x
|
3.55
x
|
4.63
x
|
4.52
x
|
4.53
x
|
EV / EBITDA
|
18.2
x
|
10.5
x
|
10.1
x
|
13.8
x
|
13.7
x
|
13
x
|
EV / FCF
|
-29.7
x
|
-20.4
x
|
-18.3
x
|
-37.1
x
|
-35.1
x
|
-57.4
x
|
FCF Yield
|
-3.37%
|
-4.91%
|
-5.46%
|
-2.69%
|
-2.85%
|
-1.74%
|
Price to Book
|
2.68
x
|
2.5
x
|
1.69
x
|
1.84
x
|
1.78
x
|
1.76
x
|
Nbr of stocks (in thousands)
|
93,133
|
93,133
|
93,133
|
93,133
|
93,133
|
93,133
|
Reference price
2 |
25.19
|
27.31
|
20.32
|
24.41
|
25.10
|
26.40
|
Announcement Date
|
10/18/18
|
11/24/19
|
10/28/20
|
12/6/21
|
12/4/22
|
1/4/24
|
Fiscal Period: June |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net sales
1 |
396
|
602
|
534
|
495.1
|
530.5
|
558
|
EBITDA
1 |
121.5
|
237.1
|
188.5
|
166.1
|
175
|
194
|
EBIT
1 |
97.33
|
212.4
|
155.4
|
127.9
|
133.3
|
135.4
|
Operating Margin
|
24.57%
|
35.29%
|
29.1%
|
25.84%
|
25.13%
|
24.26%
|
Earnings before Tax (EBT)
1 |
94.61
|
212
|
161.5
|
134.2
|
130.3
|
128.6
|
Net income
1 |
86.88
|
158.4
|
117.1
|
113.6
|
97.53
|
98.64
|
Net margin
|
21.94%
|
26.31%
|
21.92%
|
22.94%
|
18.39%
|
17.68%
|
EPS
2 |
1.171
|
1.701
|
1.257
|
1.220
|
1.047
|
1.059
|
Free Cash Flow
1 |
-74.5
|
-122.1
|
-103.5
|
-61.67
|
-68.27
|
-44.03
|
FCF margin
|
-18.81%
|
-20.29%
|
-19.37%
|
-12.46%
|
-12.87%
|
-7.89%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
2 |
0.1473
|
0.1621
|
-
|
0.1961
|
0.2000
|
0.2000
|
Announcement Date
|
10/18/18
|
11/24/19
|
10/28/20
|
12/6/21
|
12/4/22
|
1/4/24
|
Fiscal Period: June |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net Debt
1 |
-
|
-
|
2.59
|
17.2
|
59.6
|
70.5
|
Net Cash position
1 |
135
|
54.5
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
0.0137
x
|
0.1037
x
|
0.3406
x
|
0.3636
x
|
Free Cash Flow
1 |
-74.5
|
-122
|
-103
|
-61.7
|
-68.3
|
-44
|
ROE (net income / shareholders' equity)
|
11.7%
|
16.7%
|
10.9%
|
9.65%
|
7.66%
|
7.27%
|
ROA (Net income/ Total Assets)
|
6.99%
|
12%
|
7.53%
|
5.53%
|
5.27%
|
4.93%
|
Assets
1 |
1,243
|
1,325
|
1,554
|
2,054
|
1,852
|
2,001
|
Book Value Per Share
2 |
9.380
|
10.90
|
12.00
|
13.30
|
14.10
|
15.00
|
Cash Flow per Share
2 |
2.000
|
0.9500
|
0.0700
|
0.0300
|
0.0500
|
0.0100
|
Capex
1 |
147
|
273
|
212
|
184
|
191
|
203
|
Capex / Sales
|
37.08%
|
45.4%
|
39.78%
|
37.18%
|
36.03%
|
36.33%
|
Announcement Date
|
10/18/18
|
11/24/19
|
10/28/20
|
12/6/21
|
12/4/22
|
1/4/24
|
|
1st Jan change
|
Capi.
|
---|
| +11.65% | 22.55M | | -7.33% | 81.21B | | +33.75% | 3.99B | | +0.70% | 3.38B | | +21.28% | 1.76B | | -2.34% | 1.28B | | -38.81% | 1.01B | | -43.09% | 950M | | -19.59% | 843M | | -36.06% | 833M |
Veterinary Drugs
|